Study guide
7.3 Basic Cancer Epidemiology & Descriptive Statistics
NCRA Oncology Data Specialist ODS-C
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The ODS-C Exam, the Oncology Data Specialist Profession & Standard Setters
1.1 ODS Exam Structure, Timing, Scoring & 2026 Testing Windows 1.2 From CTR to ODS: The Credential, Eligibility Routes & the Registrar's Role 1.3 Standard-Setting Organizations & the Manuals They Publish
2 Chapter 2: Legal Framework, HIPAA & State Reporting Laws
2.1 HIPAA Privacy Rule & the Public Health Reporting Exception 2.2 HIPAA Security Rule, Safeguards & Breach Notification 2.3 State Mandatory Cancer Reporting Laws & Statutory Authority
3 Chapter 3: Confidentiality, Release of Information, Ethics & Credential Maintenance
3.1 Patient Confidentiality Protocols & Data Access Policies 3.2 Handling Subpoenas, Discovery & Registry Immunity Statutes 3.3 NCRA Code of Ethics & ODS Credential Maintenance
4 Chapter 4: Registry Organization, Staffing & Information Systems
4.1 Types of Cancer Registries, Their Functions & Registry Operating Protocols 4.2 Registry Staffing Formulas, Time Studies & Resource Allocation 4.3 Electronic Registry Systems, Security & Disaster Recovery Planning
5 Chapter 5: Cancer Committee, Cancer Conferences & Quality Improvement
5.1 The Cancer Committee: CoC Standards 2.1–2.4, the CLP & Annual Program Activities 5.2 Multidisciplinary Cancer Case Conferences (CoC Standard 2.5) 5.3 Quality Improvement Principles & CoC Chapter 7 (Standards 7.1–7.3)
6 Chapter 6: CoC Accreditation Standards, NCDB & Data Quality
6.1 CoC Accreditation: Standards Structure, Program Categories & Accreditation Awards 6.2 The National Cancer Database (NCDB), RCRS Submission & CoC Quality Measures 6.3 Quality Control Plans & Audit Techniques (CoC Standard 6.1)
7 Chapter 7: Surveillance Programs, NAACCR Standards, Epidemiology & Statistics
7.1 National Cancer Surveillance Programs: SEER & CDC NPCR 7.2 NAACCR Data Exchange Standards, XML Data Specifications & Registry Certification 7.3 Basic Cancer Epidemiology & Descriptive Statistics 7.4 Basic Statistics: Frequency Distributions, Central Tendency, Risk Ratios & Odds Ratios 7.5 Survival Analysis, Life Tables & Presentation of Registry Data
8 Chapter 8: Medical Terminology, Anatomy & Types of Cancer
8.1 Medical Terminology & Standard Abbreviations for Cancer Abstracting 8.2 Human Anatomy & Physiology for Registrars: Tissues, Organ Walls, Subsites & Lymphatic Drainage 8.3 Types & Characteristics of Cancer: Benign vs. Malignant, Tumor Families, Spread & Precursors
9 Chapter 9: Casefinding & Reportability
9.1 Principles of Casefinding & Facility Reference Dates 9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs 9.3 Reportability: What CoC, SEER and NPCR Require, Including Non-Malignant CNS Tumors 9.4 Ambiguous Terminology: Reportable Terms, Cytology, Discrepancies & "References of Last Resort"
10 Chapter 10: Diagnostic Procedures, Pathology Reporting, Lab Methods & Prognostic Indicators
10.1 Diagnostic & Staging Procedures: Imaging, Endoscopy, Biopsy & How They Are Coded 10.2 Pathology Reporting, CAP Cancer Protocols & Electronic Pathology (CoC Standard 5.1) 10.3 Specialty Laboratory Testing Methods: IHC, FISH, PCR/RT-PCR, NGS, Flow Cytometry & Cytogenetics 10.4 Prognostic Indicators & Site-Specific Data Items (SSDIs): HPV, KRAS, HER2 and More
11 Chapter 11: Class of Case, Key Dates & Case Identifiers
11.1 Class of Case, Date of First Contact, Date of Diagnosis & Accession/Sequence Numbers 11.2 Analytic Classes of Case (00, 10–14, 20–22): Definitions & Decision Rules 11.3 Nonanalytic Classes of Case (30–49, 99) & Why Central Registries Need Them
12 Chapter 12: Follow-Up, Vital Status & Recurrence
12.1 Follow-Up Purpose, Active & Passive Methods, and Follow-Up Source Codes 12.2 CoC Standard 6.5 Follow-Up Rates: Windows, Exclusions & Calculations 12.3 Vital Status, Date of Last Contact, Cancer Status & Death Clearance 12.4 Recurrence: Type of First Recurrence [1880], Date of First Recurrence [1860] & Recurrence vs. New Primary
13 Chapter 13: Abstracting, ICD-O-3.2 Site & Histology Coding, and Grade
13.1 The Abstracting Process: Workflow, Source Documents, Timeliness & Text Documentation 13.2 ICD-O-3.2 Topography, Primary Site Rules & Laterality 13.3 ICD-O-3.2 Morphology: Histology, Behavior & the Solid Tumor Histology Rules 13.4 Grade: The Four Time-Specific Grade Items & Site-Specific Grade Tables
14 Chapter 14: Solid Tumor Rules & Hematopoietic Coding Rules
14.1 Solid Tumor Rules: Purpose, Site Groups, Navigation & Timing Principles 14.2 Solid Tumor Rules for Breast, Colon/Rectum & Lung: The Multiple Primary Rules in Order 14.3 Solid Tumor Rules for Head & Neck, Kidney, Urinary, CNS, Melanoma & Other Sites 14.4 Hematopoietic & Lymphoid Neoplasms: Heme Manual, Heme DB, Multiple Primary & Primary Site Rules
15 Chapter 15: Staging: AJCC TNM (8th Edition & Version 9 Lung) and Summary Stage 2018
15.1 AJCC TNM Principles: Categories, Prefixes, Suffixes, General Rules & Registry Items 15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy 15.3 Breast Staging (AJCC 8th Edition, Part XI): T, N, M, Anatomic & Prognostic Stage Groups 15.4 Lung Staging (AJCC Version 9, 2025+): T, N2a/N2b, M1c1/M1c2 & New Stage Groups 15.5 Male Genital & Urinary Tract Staging (AJCC 8th Parts XIII–XIV): Prostate, Testis, Kidney, Bladder, Renal Pelvis & Ureter 15.6 SEER Summary Stage 2018: Codes, Timing, General Rules & Site Examples
16 Chapter 16: First-Course Treatment Coding (STORE 2025) & EDITS
16.1 Treatment Types, First Course of Treatment & Evidence-Based Guidelines (NCCN) 16.2 Surgery Coding: Rx Summ–Surg 2023 [1291], Lymph Node Surgery [1292], Other Site [1294], Margins & Reason for No Surgery 16.3 Radiation, Systemic, Transplant, Other & Palliative Treatment Coding (STORE 2025) 16.4 NAACCR EDITS, Over-ride Flags & Data Validation
7.3 Basic Cancer Epidemiology & Descriptive Statistics
Key Takeaways Explain This Topic AI
Cancer incidence measures the rate of newly diagnosed cases in a defined population at risk over a specified time period, typically expressed per 100,000 persons per year.
Cancer prevalence represents the total number of individuals alive with a prior cancer diagnosis at a given point in time (stock), in contrast to incidence which measures new occurrences (flow).
Cancer mortality measures death rates in the general midyear population (per 100,000), whereas the Case Fatality Rate measures the proportion of diagnosed cancer patients who die from the disease.
Age adjustment using the Direct Method eliminates the confounding effects of disparate population age structures by applying age-specific rates to the standard 2000 United States Population weights.
Age-adjusted rates are artificial relative comparative indices suitable for tracking temporal trends and cross-geographic comparisons, but cannot be used to calculate actual patient counts.
Last updated: September 2026
7.3 Basic Cancer Epidemiology & Descriptive Statistics
Epidemiology is the foundational quantitative discipline of public health, defined as the study of the distribution and determinants of health-related states and events in specified populations, and the application of this study to control health problems. In oncology data management, descriptive epidemiology provides the analytical vocabulary needed to characterize cancer patterns by person (who develops cancer), place (where cancer rates are elevated or suppressed), and time (how cancer risk shifts over decades).
To interpret cancer surveillance reports, evaluate registry quality, and succeed on the ODS-C examination, oncology data specialists must command core epidemiologic measures: incidence, prevalence, mortality, and the biostatistical principles governing age adjustment.
Cancer Incidence: Measuring the Flow of New Cases
Incidence quantifies the occurrence of newly diagnosed disease. In cancer surveillance, the cancer incidence rate measures the probability or frequency with which previously unaffected individuals in a specified population develop cancer during a defined calendar period.
Mathematical Formula for Incidence Rate
Annual Cancer Incidence Rate = ( Number of Newly Diagnosed Cancer Cases in Calendar Year Total Population at Risk at Midyear ) × 100 , 000 \text{Annual Cancer Incidence Rate} = \left( \frac{\text{Number of Newly Diagnosed Cancer Cases in Calendar Year}}{\text{Total Population at Risk at Midyear}} \right) \times 100,000 Annual Cancer Incidence Rate = ( Total Population at Risk at Midyear Number of Newly Diagnosed Cancer Cases in Calendar Year ) × 100 , 000
Key Components of the Incidence Rate
Numerator: The count of new primary malignant neoplasm diagnoses occurring between January 1 and December 31. Recurrent cancers or existing cases diagnosed in prior years are strictly excluded.
Denominator (Population at Risk): The number of individuals in the geographic area who are biologically capable of developing the malignancy. For general cancer incidence, the midyear (July 1) census population estimate is used. For sex-specific cancers, the denominator is restricted:
Uterine, Ovarian, or Cervical Cancer: Denominator must include only the female population at risk (and in refined clinical models, women who have undergone complete hysterectomy or bilateral oophorectomy are removed).
Prostate Cancer: Denominator must include only the male population at risk.
Constant Multiplier: Cancer rates are universally standardized per 100,000 population (written as "per 100,000 person-years"). This standard base permits direct comparison between small rural counties and massive metropolitan states.
Cancer Prevalence: Measuring the Total Disease Burden
While incidence measures the rate of new events, prevalence measures the total burden of disease in a community at a specific cross-section in time. Cancer prevalence represents the total number or proportion of individuals alive who have ever received a cancer diagnosis, regardless of whether they are currently undergoing active treatment, living in complete remission, or cured.
Point Prevalence vs. Period Prevalence
Point Prevalence: The proportion of living persons with a history of cancer at an exact calendar date (e.g., January 1, 2026).
Period Prevalence: The proportion of persons with a cancer diagnosis who were alive at any point during a designated time window (e.g., a 5-year prevalence window from 2021 through 2025).
- The Relationship Between Incidence, Duration, and Prevalence ┌───────────────────────────┐
- │ INCIDENCE (Inflow) │
- │ New Primary Diagnoses │
- └─────────────┬─────────────┘
- │
- ▼
- ┌────────────────────────────────────────────────────────┐
- │ PREVALENCE POOL (Stock) │
- │ All Living Individuals with a Cancer History │
- └────────────────────────────┬───────────────────────────┘
- │
- ┌──────────────┴──────────────┐
- ▼ ▼
- ┌──────────────┐ ┌──────────────┐
- │ CURE or │ │ MORTALITY │
- │ EMIGRATION │ │ (Outflow) │
- └──────────────┘ └──────────────┘
In epidemiologic steady-state conditions, prevalence is mathematically approximated as:
Prevalence ≈ Incidence Rate × Average Survival Duration \text{Prevalence} \approx \text{Incidence Rate} \times \text{Average Survival Duration} Prevalence ≈ Incidence Rate × Average Survival Duration
This dynamic leads to vital clinical distinctions tested on the ODS-C exam:
Short Survival (Low Prevalence Relative to Incidence): Pancreatic adenocarcinoma and glioblastoma have short median survival, often around a year. Even though thousands of new cases are diagnosed annually, the prevalence pool stays small because patients leave it quickly through death.
Moderate Incidence, Long Survival (High Prevalence): Early-stage breast cancer, localized prostate cancer, and cutaneous melanoma have high 5-year and 10-year relative survival rates (> 90%). Consequently, survivors accumulate in the population year after year, generating immense prevalence pools requiring long-term survivorship care.
Cancer Mortality vs. Case Fatality Rate
Registrars must never confuse a population-based mortality rate with a clinical case fatality rate (CFR) . Although both metrics incorporate cancer deaths, their denominators and public health interpretations differ fundamentally.
Annual Cancer Mortality Rate
The mortality rate reflects the risk of dying from a specific cancer for an individual in the general population :
Annual Cancer Mortality Rate = ( Number of Cancer Deaths in Calendar Year Total Midyear General Population ) × 100 , 000 \text{Annual Cancer Mortality Rate} = \left( \frac{\text{Number of Cancer Deaths in Calendar Year}}{\text{Total Midyear General Population}} \right) \times 100,000 Annual Cancer Mortality Rate = ( Total Midyear General Population Number of Cancer Deaths in Calendar Year ) × 100 , 000
Mortality data are derived from official death certificates compiled by state vital statistics offices and the National Center for Health Statistics (NCHS), coded according to the International Classification of Diseases (ICD-10) underlying cause of death.
Case Fatality Rate (CFR)
The case fatality rate measures the clinical virulence or lethality of a disease among diagnosed individuals :
Case Fatality Rate (%) = ( Number of Deaths Due to Specific Cancer in Cohort Total Number of Individuals Diagnosed with that Cancer ) × 100 \text{Case Fatality Rate (\%)} = \left( \frac{\text{Number of Deaths Due to Specific Cancer in Cohort}}{\text{Total Number of Individuals Diagnosed with that Cancer}} \right) \times 100 Case Fatality Rate (%) = ( Total Number of Individuals Diagnosed with that Cancer Number of Deaths Due to Specific Cancer in Cohort ) × 100
- Dimension Cancer Mortality Rate Case Fatality Rate (CFR)
- Numerator Deaths from cancer in a calendar year Deaths from cancer in a diagnosed cohort
- Denominator Total general midyear population (healthy + ill) Diagnosed patients with that cancer
- Multiplier Per 100,000 population Percentage (%)
- Focus Population disease impact and public health burden Biological virulence and clinical treatment efficacy
- Crude Rates vs. Specific Rates
When presenting cancer statistics, data can be expressed at varying levels of demographic aggregation:
Crude Rate: The total number of cancer cases (or deaths) divided by the total population, with no adjustment for demographic composition. While crude rates reflect the actual numerical volume of cases that healthcare systems must manage, they are profoundly misleading when comparing different geographic areas or historical eras because they fail to account for population age structures.
Category-Specific Rates: Rates calculated exclusively for a specific demographic stratum:
Age-Specific Rate: Rate computed within a defined age band (e.g., females aged 50–54 years): Age-Specific Rate i = ( Cases in Age Group i Population in Age Group i ) × 100 , 000 \text{Age-Specific Rate}_{i} = \left( \frac{\text{Cases in Age Group } i}{\text{Population in Age Group } i} \right) \times 100,000 Age-Specific Rate i = ( Population in Age Group i Cases in Age Group i ) × 100 , 000
Sex-Specific Rate: Rate computed separately for males or females.
Race/Ethnicity-Specific Rate: Rate computed within specific racial or ethnic cohorts.
Age Adjustment: The Direct Method
Because cancer incidence increases exponentially with advancing age, age is the single most powerful confounding variable in cancer epidemiology. If Region A has a retirement community where 40% of the population is over age 65, its crude cancer rate will appear drastically higher than Region B, where only 12% of the population is over 65—even if an individual living in Region B actually faces a higher personal risk of developing cancer.
To eliminate the confounding effect of differing age structures, biostatisticians calculate Age-Adjusted (Age-Standardized) Rates .
The Standard Population: 2000 United States Standard
In 1998, the United States Department of Health and Human Services (HHS) mandated that all federal health agencies adopt the 2000 United States Standard Population (replacing the historical 1940 and 1970 standards) beginning with 1999 data. The standard population provides a fixed, predetermined distribution of demographic weights ( w i w_i w i ) across age groups, where the sum of all weights equals 1.0 ( ∑ w i = 1.0 \sum w_i = 1.0 ∑ w i = 1.0 ).
The Direct Method of Age Adjustment Workflow
Under the Direct Method , the age-specific rates observed in the study population are multiplied by the corresponding proportion of the standard population in that age group, and the products are summed across all age groups:
Age-Adjusted Rate = ∑ i = 1 k ( Age-Specific Rate i × w i ) \text{Age-Adjusted Rate} = \sum_{i=1}^{k} \left( \text{Age-Specific Rate}_{i} \times w_{i} \right) Age-Adjusted Rate = ∑ i = 1 k ( Age-Specific Rate i × w i )
Where:
Age-Specific Rate i \text{Age-Specific Rate}_{i} Age-Specific Rate i = The observed rate in age group i i i per 100,000
w i = Standard Population in Age Group i Total Standard Population w_{i} = \frac{\text{Standard Population in Age Group } i}{\text{Total Standard Population}} w i = Total Standard Population Standard Population in Age Group i (the age-specific standard weight)
Calculation Walkthrough: Direct Age Adjustment
Consider a simplified hypothetical population evaluated across three broad age strata using the standard population distribution:
Age Stratum Local Cases Local Population Local Age-Specific Rate (per 100,000) 2000 US Standard Proportion ( w i w_i w i ) Weighted Rate Contribution
0–39 Years 30 100,000 ( 30 / 100 , 000 ) × 100 , 000 = 30.0 (30 / 100,000) \times 100,000 = \mathbf{30.0} ( 30/100 , 000 ) × 100 , 000 = 30.0 0.55 30.0 × 0.55 = 16.50 30.0 \times 0.55 = \mathbf{16.50} 30.0 × 0.55 = 16.50
40–64 Years 180 60,000 ( 180 / 60 , 000 ) × 100 , 000 = 300.0 (180 / 60,000) \times 100,000 = \mathbf{300.0} ( 180/60 , 000 ) × 100 , 000 = 300.0 0.30 300.0 × 0.30 = 90.00 300.0 \times 0.30 = \mathbf{90.00} 300.0 × 0.30 = 90.00
65+ Years 400 40,000 ( 400 / 40 , 000 ) × 100 , 000 = 1000.0 (400 / 40,000) \times 100,000 = \mathbf{1000.0} ( 400/40 , 000 ) × 100 , 000 = 1000.0 0.15 1000.0 × 0.15 = 150.00 1000.0 \times 0.15 = \mathbf{150.00} 1000.0 × 0.15 = 150.00
Total / Summary 610 200,000 Crude Rate: 305.0 per 100,000 Sum of Weights: 1.00 Age-Adjusted: 256.5 per 100,000
In this population, the crude incidence rate is ( 610 / 200 , 000 ) × 100 , 000 = 305.0 (610 / 200,000) \times 100,000 = \mathbf{305.0} ( 610/200 , 000 ) × 100 , 000 = 305.0 per 100,000. However, after removing the distortion of local age demographics through the Direct Method, the age-adjusted incidence rate is 256.5 \mathbf{256.5} 256.5 per 100,000.
Exam Watch: An age-adjusted rate is a relative index number , not an absolute biological reality. It represents the rate that would have occurred if the local population had the exact same age distribution as the standard population. You can compare age-adjusted rates between counties to identify true disparities, but you cannot multiply an age-adjusted rate by local population size to determine how many hospital beds or chemotherapy chairs are needed!
- Practice Scenario & Exam Pitfalls
- Clinical Practice Scenario
A hospital cancer committee is reviewing regional registry reports. County X reports a crude colon cancer incidence rate of 58.2 per 100,000, while County Y reports a crude rate of 41.5 per 100,000. A physician asserts that County X must have higher environmental carcinogen exposure. The ODS-C checks the age-adjusted rates and discovers County X's age-adjusted rate is 39.1 per 100,000, while County Y's is 44.8 per 100,000.
Epidemiologic Analysis: County X has a substantially older population (e.g., retirement communities), which artificially inflated its crude rate. When age confounding is controlled via age adjustment, County Y actually has the higher cancer risk. Environmental or lifestyle investigation should focus on County Y.
Core Exam Pitfalls to Avoid
Pitfall 1: Confusing mortality rate with case fatality rate. A mortality rate denominator is the entire general population (healthy individuals included); a case fatality rate denominator contains only individuals diagnosed with the disease.
Pitfall 2: Using age-adjusted rates to estimate resource needs. Age-adjusted rates are artificial indices valid solely for comparative analysis. To plan clinical hospital capacity, operating rooms, or staffing, healthcare administrators must utilize crude counts and crude rates .
Pitfall 3: Failing to restrict denominators for sex-specific cancers. Calculating prostate cancer incidence against the total population (including women) roughly halves the true rate and is a basic statistical error.